OAS1 Splice Site Polymorphism Controlling Antiviral Enzyme Activity Influences Susceptibility to Type 1 Diabetes
Overview
Authors
Affiliations
Both genetic and nongenetic factors contribute to the development of type 1 diabetes. Many investigations, including prospective studies of high-risk children, have implicated virus infections as predisposing environmental agents. We previously reported that basal activity of the key antiviral enzyme 2'5'-oligoadenylate synthetase (2'5'AS) was significantly elevated in type 1 diabetic patients compared with healthy control subjects. Recently, we showed that an A/G splice site single nucleotide polymorphism (SNP) in the OAS1 gene encoding 2'5'AS is strongly associated with basal 2'5'AS activity. Basal enzyme activity was highest in individuals with GG genotype and lowest in those with AA genotype. In the present study, we genotyped 835 type 1 diabetic and 401 healthy siblings at the OAS1 splice site polymorphism and (for comparison) at an A/C SNP of the insulin (IDDM2) locus. Results showed that OAS1 GG and GA were significantly increased in diabetic compared with healthy siblings (P = 0.0023). The strength of association was similar to that at IDDM2, where, as expected, the C/C (variable number tandem repeat class I homozygote) genotype was increased in affected compared with healthy siblings (P = 0.0025). The results suggest that host genetic response to virus infection could influence susceptibility to type 1 diabetes.
De Jesus D, Zhang Z, Brown N, Li X, Xiao L, Hu J Nat Cell Biol. 2024; 26(3):421-437.
PMID: 38409327 PMC: 11042681. DOI: 10.1038/s41556-024-01368-0.
Pan-cancer analysis identified OAS1 as a potential prognostic biomarker for multiple tumor types.
Jiang S, Deng X, Luo M, Zhou L, Chai J, Tian C Front Oncol. 2023; 13:1207081.
PMID: 37746262 PMC: 10511872. DOI: 10.3389/fonc.2023.1207081.
2-5A-Mediated decay (2-5AMD): from antiviral defense to control of host RNA.
Prangley E, Korennykh A Crit Rev Biochem Mol Biol. 2023; 57(5-6):477-491.
PMID: 36939319 PMC: 10576847. DOI: 10.1080/10409238.2023.2181308.
Identification and validation of key biomarkers for the early diagnosis of diabetic kidney disease.
Yu W, Wang T, Wu F, Zhang Y, Shang J, Zhao Z Front Pharmacol. 2022; 13:931282.
PMID: 36071835 PMC: 9441656. DOI: 10.3389/fphar.2022.931282.
Schwartz S, Dey D, Tanquary J, Bair C, Lowen A, Conn G Proc Natl Acad Sci U S A. 2022; 119(3).
PMID: 35017296 PMC: 8784149. DOI: 10.1073/pnas.2107111119.